Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Receivables: 2019-2021

  • 4D Molecular Therapeutics' Receivables fell 49.73% to $747,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $4.2 million, marking a year-over-year change of. This contributed to the annual value of $747,000 for FY2021, which is 49.73% down from last year.
  • As of Q4 2021, 4D Molecular Therapeutics' Receivables stood at $747,000, which was down 5.56% from $791,000 recorded in Q3 2021.
  • 4D Molecular Therapeutics' Receivables' 5-year high stood at $1.5 million during Q4 2020, with a 5-year trough of $747,000 in Q4 2021.
  • Its 3-year average for Receivables is $1.0 million, with a median of $959,000 in 2019.
  • Its Receivables has fluctuated over the past 5 years, first surged by 31.85% in 2020, then slumped by 49.73% in 2021.
  • Over the past 3 years, 4D Molecular Therapeutics' Receivables (Quarterly) stood at $1.1 million in 2019, then skyrocketed by 31.85% to $1.5 million in 2020, then crashed by 49.73% to $747,000 in 2021.
  • Its Receivables was $747,000 in Q4 2021, compared to $791,000 in Q3 2021 and $1.5 million in Q4 2020.